Akt, AS160, metabolic risk factors and aerobic fitness in middle-aged women by Levinger, Itamar et al.
Deakin Research Online 
Deakin University’s institutional research repository 
DDeakin Research Online  
Research Online  
This is the published version (version of record) of: 
 
Levinger, Itamar, Howlett, Kirsten F., Peake, Jonathan, Garnham, 
Andrew, Hare, David L., Jerums, George, Selig, Steve and Goodman, 
Craig 2010, Akt, AS160, metabolic risk factors and aerobic fitness in 
middle-aged women, Exercise immunology review, vol. 16, pp. 98-104. 
 
Available from Deakin Research Online:  
 
http://hdl.handle.net/10536/DRO/DU:30033425 
 
Reproduced with kind permission of the copyright owner. 
 
 
Copyright : 2010, Human Kinetics 
 
 
 
Akt, AS160, metabolic risk factors and aerobic
fitness in middle-aged women
Itamar Levinger1, Kirsten F. Howlett2, Jonathan Peake3, Andrew
Garnham2, David L. Hare4, George Jerums5, Steve Selig1, Craig Goodman1.
1 Institute of Sport, Exercise and Active Living, School of Sport and Exercise
Science, Victoria University, Melbourne, AUSTRALIA
2 School of Exercise and Nutrition Sciences, Deakin University, Melbourne,
AUSTRALIA
3 The University of Queensland, School of Human Movement Studies, Brisbane
AUSTRALIA
4 University of Melbourne and the Department of Cardiology, Austin Health,
Melbourne, AUSTRALIA
5 University of Melbourne and the Department of Endocrinology, Austin Health,
Melbourne, AUSTRALIA
ABSTRACT
Aims: This study investigated the association between the basal (rest) insulin-sig-
naling proteins, Akt, and the Akt substrate AS160, metabolic risk factors, inflam-
matory markers and aerobic fitness, in middle-aged women with varying numbers
of metabolic risk factors for type 2 diabetes. Methods: Sixteen women (n=16)
aged 51.3±5.1 (mean ±SD) years provided muscle biopsies and blood samples at
rest. In addition, anthropometric characteristics and aerobic power were asses-
sed and the number of metabolic risk factors for each participant was determined
(IDF criteria). Results: The mean number of metabolic risk factors was 1.6±1.2.
Total Akt was negatively correlated with IL-1β (r = −0.45, p = 0.046), IL-6 (r =
−0.44, p = 0.052) and TNF-α (r = −0.51, p = 0.025). Phosphorylated AS160 was
positively correlated with HDL (r = 0.58, p= 0.024) and aerobic fitness (r = 0.51,
p=0.047). Furthermore, a multiple regression analysis revealed that both HDL
(t=2.5, p=0.032) and VO2peak (t=2.4, p=0.037) were better predictor for phos-
phorylated AS160 than TNF-α or IL-6 (p>0.05). Conclusions: Elevated inflam-
matory markers and increased metabolic risk factors may inhibit insulin-signa-
ling protein phosphorylation in middle-aged women, thereby increasing insulin
resistance under basal conditions. Furthermore, higher HDL and fitness levels
are associated with an increase AS160 phosphorylation, which may in turn redu-
ce insulin resistance.
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INTRODUCTION
Individuals with clusters of metabolic risk factors for metabolic syndrome and
type 2 diabetes (T2DM) present with increased inflammation (16). Increased
inflammation, indicated by elevated plasma concentrations of tumor necrosis fac-
tor (TNF)-α, interleukin (IL)-6, IL-8 and C-reactive protein (CRP) may lead to
abnormal glucose homeostasis, insulin resistance and type 2 diabetes (T2DM) (5,
7, 11). A possible contributor for the increase in inflammatory markers in middle-
aged individuals is poor fitness level and increased visceral fat (2). The mecha-
nism by which inflammatory markers affect insulin resistance is not fully under-
stood. TNF-α (10, 11), CRP (5) and other low grade inflammatory markers, such
as, IL-6 and IL-8, may lead to insulin resistance by inhibiting the phosphorylation
of the insulin receptor substrate (IRS)-1, which in turn may impair downstream
signaling (5). Akt and its 160 kDa (AS160) substrate are important downstream
proteins in the phosphatidylinositol 3-kinase (PI3-K) pathway, and are proposed
to form a link between the insulin-signaling cascade, and glycogen and protein
synthesis (14). AS160 may also represent a common convergence point between
the pathways regulating insulin and contraction stimulated GLUT-4 translocation
(4). Insulin stimulated phosphorylation of both Akt (13) and AS160 (12) is
reduced in individuals with T2DM during hyperinsulineamic clamp, compared to
healthy controls. In addition, it has been reported that TNF-α treatment complete-
ly blocked insulin action on both Akt and AS160 leading to insulin resistance (3)
Whether an association exists between metabolic risk factors, inflammatory
markers, aerobic fitness and the phosphorylation of Akt and AS160 under basal
conditions in middle-aged women is uncertain. Such associations are potentially
important, because modern day sedentary lifestyles involve long periods of rest
(including sleeping) or low-intensity activities of daily living. During these peri-
ods, food is not consumed, and therefore insulin levels are relatively low. We
examined the association between metabolic risk factors, inflammatory markers,
aerobic fitness and the phosphorylation of Akt and AS160 under basal conditions
in women with varying numbers of metabolic risk factors. We hypothesized that
elevated plasma concentrations of inflammatory markers and metabolic risk fac-
tors would be associated with reduced basal levels of Akt and AS160 (total and
phosphorylation forms).
PATIENTSAND METHODS
Participants
Sixteen women (n=16) aged 51.3±5.1 (mean ±SD) years participated in the study.
After initial medical assessment each participant was classified as having 0, 1, 2,
3 or 4 risk factors for metabolic syndrome as published by the International Dia-
betes Federation (18). These criteria include: waist circumference ≥80 cm for
women, triglycerides ≥ 1.7mmol·L-1, high density lipoprotein (HDL) <1.29
mmol·L-1 for women, systolic blood pressure ≥130 mmHg and/or diastolic blood
pressure ≥85 mmHg (or hypertensive medications) and fasting blood glucose
level ≥5.6 mmol·L-1. Participants also provided muscle samples and additional
blood to measure the plasma concentrations of cytokines and CRP. One partici-
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pant was using a beta-blocker and five were undergoing hormone replacement
therapy. Each participant received written and verbal explanations about the
nature of the study before giving informed consent. The study protocol was
approved by the Human Research Ethics Committees of both Victoria University
and Austin Health.
Procedures
Blood samples: Details of the blood collection and analysis have been reported
previously (16). In brief, blood samples were collected after 12 hours of fasting.
The blood was centrifuged and plasma was analysed for high sensitivity CRP
using an automated analyser (SYNCHRON LX ® System/Lxi725, Beckman,
USA). IL-1β, IL-6, IL-8 and TNFα were analysed using high sensitivity multi-
plex assays (Human High-Sensitivity Cytokine assay, LincoPlex, Millipore, Bil-
lerica, MA, USA), according to the manufacturer’s protocol. Insulin resistance
was estimated by the homeostasis model assessment (HOMA-IR). HOMA-IR
was calculated from fasting glucose and insulin:
Insulin resistance = fasting glucose (mmol·L-1) × fasting insulin (µU·ml-1)/22.5 (9).
Aerobic power (VO2peak): Complete details of the VO2peak assessment have been
reported previously (15). In brief, VO2peak was assessed during a symptom-limited
graded exercise test on a Cybex MET 100 cycle ergometer (Cybex Metabolic Sys-
tems, Ronkonkoma, NY, USA). The protocol consisted of an initial intensity of 25
W, with increments of 20 W.min-1 for males and 10 W.min-1 for females. The
tests were terminated when participants’ ratings of perceived exertion reached
“very hard” (Borg scale = 17). VO2 for each 15 sec interval was measured by gas
analysis (Medgraphics, Cardio2 and CPX/D System with Breezeex Software,
142090-001, Revia, MN, USA) that was calibrated before each test.
Muscle biopsy: Resting muscle samples were taken from the vastus lateralis under
local anesthesia with Xylocaine 1%, utilizing the percutaneous needle biopsy
technique with suction (8). The samples were immediately frozen in liquid nitro-
gen and were then stored at –80ºC until analysis.
Muscle Sample Preparation: Muscle (25−47 mg) was homogenised (Kinematica
Polytron, Brinkmann, CT) in ice-cold lysis buffer consisting of 20 mmol•L-1
Tris-HCl, 5 mmol•L-1 EDTA, 10 mmol•L-1 Na-pyrophosphate, 100 mmol•L-1
NaF, 2 mmol•L-1 Na3VO4, 1% NP-40, and protease inhibitor tablet (Roche,
Lewes, Sussex, UK). Homogenised muscle was incubated for 30 min at 4ºC and
then centrifuged at 13000 g for 30 min. The supernatant was stored at –80ºC.
Total protein determination: Total protein concentration was determined using
BCA Pearce protein assay kit (Pierce Biotechnology, IL, USA ) using BSA as
standard.
Antibodies: The phospho-Akt substrate (Ser/Thr) antibody, phospho-Akt
(Ser473) antibody and Akt antibody were supplied by Cell Signaling Technology
(Beverly, MA), and Anti-AS160 (Rab-GAP) was supplied from Upstate (NY,
USA).
Blotting: Proteins were separated using 8% SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and then transferred to nitrocellulose membranes. The
membranes were blocked with 5% BSA in Tris-buffered saline with 0.5% Tween
(TBST) at room temperature for 1 h. Membranes were incubated overnight at 4ºC
with antibodies, diluted (1:2000) in blocking buffer. Membranes were washed
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with TBST and protein was detected using secondary rabbit HRP-conjugated
antibody (Cell Signaling Technology, MA, USA). Proteins were viewed by
chemiluminescence (Western Lighting Chemiliuminescence Reagent Plus, Perkin
Elmer, Boston, MA) and bands were quantified using Kodak Imaging software
(Kodak ID 3.5, Boston, MA).
Statistics
Spearman Rho correlations were used to assess the relationship between Akt and
AS160 and inflammatory markers and metabolic risk factors. Correlations were
also controlled for age and the number of metabolic risk factors for each person
(0, 1, 2, 3 or 4). Data was analyzed with
SPSS (Version 16). Data are reported as
mean ± SD and all statistical analyses were
conducted at the 95% level of significance.
RESULTS
Participants’ characteristics are presented in
Table 1. Participants presented with a range
of metabolic risk factors including obesity,
impaired fasting glucose, hypertension and
dyslipidaemia.
Total Akt was correlated with total AS160
(r = 0.70, p <0.002) and phosphorylated
Akt was correlated with phosphorylated
AS160 (r = 0.70, p<0.002).
Total Akt was negatively correlated with
IL-1β, IL-6 and TNF-α (Figure 1A, B and
C). In addition, when data were adjusted
for age, total AS160 was negatively corre-
lated with IL-6 (r = −0.58, p = 0.025), IL-8
(r = −0.51, p = 0.045), and TNF-α (r =
−0.56, p = 0.03). Phosphorylated AS160
was positively correlated with HDL (r =
0.58, p = 0.019) and aerobic fitness (r =
0.58, p = 0.018). A multiple regression
analysis revealed that both HDL (t=2.5,
p=0.032) and VO2peak (t=2.4, p=0.037)
were better predictor for phosphorylated
AS160 than TNF-α or IL-6 (p>0.05).
DISCUSSION
The main finding of the current study was
that middle-aged women inflammatory
markers correlated negatively with basal
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Table 1. Participant’s characteristics
Variable Women
(n=16)
Age (yrs) 51.3±5.1
Height (cm) 161.2±6.2
Mass (kg) 72.0±14.6
Waist (cm) 87.2±12.7
BMI (kg·m-2) 27.6±5.5
Fasting Glucose (mmol·L-1) 5.3±0.6
HOMA-IR 1.21±1.0
Triglyceride (mmol·L-1) 1.1±0.6
LDL (mmol·L-1) 3.4±0.8
HDL (mmol·L-1) 1.8±0.5
SBP (mmHg) 126.8±14.5
DBP (mmHg) 83.5±7.5
VO2peak (ml·kg-1·min-1) 21.6±4.1
IL-1β (pg·mL-1) 6.0±4.2
IL-6 (pg·mL-1) 16.8±13.9
IL-8 (pg·mL-1) 8.2±8.6
TNFα (pg·mL-1) 6.0±3.6
CRP (mg·L-1) 2.8±1.8
N of
risk factors (IDF criteria)
0 3
1 5
2 4
3 3
4 1
Total 1.6±1.2
BMI (body mass index), HOMA-IR (home-
ostasis model assessment of insulin resist-
ance), LDL (low-density lipoprotein), HDL
(high-density lipoprotein), SBP (systolic blood
pressure), DBP (diastolic blood pressure),
VO2peak (peak oxygen consumption), IL (inter-
leukin), TNFα (tumor necrosis factor alpha),
CRP (C-reactive protein), IDF (International
Diabetes Federation).
levels of both total and phosphorylated Akt
and AS160 levels. Furthermore, HDL and
aerobic fitness correlated positively with the
basal level of phosphorylated AS160.
Metabolic risk factors, insulin resistance and
T2DM are associated with increased inflam-
mation (7, 16). Inflammation may alter
insulin-signaling such as IRS-1 (11), which
in turn may impair insulin action, and there-
fore, lead to insulin resistance (10, 11). In
addition, Bouzakri and Zierath (3) have
reported the TNF-α induced insulin resist-
ance as it blocks insulin action on Akt and
AS160. In the present study we found an
association between the plasma concentra-
tions of IL-6 and IL-8 and downstream
insulin-signaling proteins (total and phos-
phorylated Akt and AS160) in women with
varying number of metabolic risk factors.
These findings support those of Bouzakri
and Zierath (3) and indicate that low-grade
inflammation inhibits not only upstream
proteins (e.g. IRS-1) but also down-stream
proteins that regulate GLUT-4 translocation
and glucose homeostasis.
Inflammatory markers IL-1β, IL-6 and
TNF-α were also associated with a reduc-
tion in total Akt and total AS160. It is
important to acknowledge that some
females were on hormone replacement ther-
apy (HRT) which may influence the interac-
tions between insulin-signaling proteins and
inflammatory cytokines. Some studies have
reported that HRT can increase inflammatory markers (such as plasma CRP con-
centration) by almost 60%,whereas other studies have reported that HRT reduces
in the plasma concentrations of IL-6 and TNF-α (for review see reference (17).
In this study, higher fitness levels and plasma HDL concentrations were associat-
ed with phosphorylatedAS160. In addition, a multiple regression analysis showed
that both HDL and aerobic fitness, but not TNF-α or IL-6, were predictors of
phosphorylated AS160 in this population. This finding is important because it
suggests that middle-aged women in general, and particularly those with metabol-
ic risk factors, should participate in aerobic exercise and other lifestyle interven-
tions such as dietary modification. When combined, these interventions improve
insulin resistance, glucose control and metabolic risk factors (for review see (1).
Arsenault et al (2) have also reported that there is a negative association between
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Figure 1. Correlation between total Akt
and IL-1β, IL-6 and TNF-α in middle-
aged women.
aerobic fitness and inflammatory markers (CRP and IL-6) in middle-aged
women. They concluded that people with low fitness levels are characterized by
increased inflammatory markers. We have provided further evidence that sys-
temic inflammation is also associated with reduced expression of insulin-signal-
ing proteins in skeletal muscle. Collectively, these findings may suggest that low
aerobic fitness is associated with increased low-grade inflammation, both of
which may have negative influence insulin-signaling proteins, leading to
increased insulin resistance.
Drew et al. (6) have recently reported that intravenous HDL treatment markedly
increases phosphorylation of acetyl-CoA carboxylase β phosphorylation (an indi-
cator of AMPK activation) in skeletal muscle of patients with T2DM. This finding
suggests that increased HDL can reduce insulin resistance in T2DM. In the cur-
rent study, we found that HDL correlates with phoshorylated AS160, which also
suggests that higher levels of HDL increase insulin-signaling phosphorylation,
which in turn may improve insulin resistance. As suggested by Drew et al, it is
possible that the mechanism involves the AMP-activated protein kinase pathway.
Larger, more detailed studies are needed to further explore the mechanisms
behind the relationship between insulin resistance, HDL levels and skeletal mus-
cle AMPK activation in this population.
In conclusion, the present data indicate that elevated systemic markers of inflam-
mation, and increased metabolic risk factors may inhibit insulin-signaling protein
phosphorylation, thereby increasing insulin resistance under basal conditions.
Furthermore, higher HDL and fitness levels are associated with an increase
AS160 phosphorylation, which may in turn reduce insulin resistance.
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